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Background: Ephrin (Eph) receptors are frequently overexpressed in a wide variety of human malignant tumors,
being associated with tumor growth, invasion, metastasis and angiogenesis. The present study aimed to evaluate
the clinical significance of EphA1, A4, A5 and A7 protein expression in non-small cell lung carcinoma (NSCLC).
Methods: EphA1, A4, A5 and A7 protein expression was assessed immunohistochemically in tissue microarrays of
88 surgically resected NSCLC and was analyzed in relation with clinicopathological characteristics and patients’
survival.
Results: Elevated EphA4 expression was significantly associated with low histopathological stage and presence of
inflammation (p = 0.047 and p = 0.026, respectively). Elevated EphA7 expression was significantly associated with
older patients’ age, presence of fibrosis and smaller tumor size (p = 0.036, p = 0.029 and p = 0.018, respectively).
EphA1, A5 and A7 expression were positively associated with tumor proliferative capacity (p = 0.047, p = 0.002 and
p = 0.046, respectively). Elevated EphA4, A5 and A7 expression were identified as predictors of favourable patients’
survival at both univariate (Log-rank test, 0 = 0.019, p = 0.006 and p = 0.012, respectively) and multivariate levels
(Cox-regression analysis, p = 0.029, p = 0.068 and p = 0.044, respectively).
Conclusions: The present study supported evidence that Ephs may be involved in lung cancer progression,
reinforcing their utility as clinical biomarkers for patients’ management and prognosis, as also as potential targets
for future therapeutic interventions.
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ImmunohistochemistryBackground
Ephrin (Eph) receptors constitute the largest sub-family
of receptor tyrosine kinases, being divided into two sub-
groups, EphA and EphB, based on their ligand-binding-
affinity and structure of the extracellular domain [1,2].
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reproduction in any medium, provided the orand EphB6) receptors have been identified in humans.
Their membrane-anchored ligands, the ephrins, are also di-
vided into two sub-groups, ephrins-A and ephrins-B, which
preferentially bind to EphA and EphB receptors, respect-
ively [1-4]. Eph/ephrin interactions occur at sites of cell to
cell contact, since both molecules are membrane bound,
or between plasma membrane clusters (microdomains)
which transform into clearly defined signaling centers
upon Eph/ephrin complex formation [5]. In this aspect,
Ephs and ephrins have been shown to form a vital celll Ltd. This is an Open Access article distributed under the terms of the Creative
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[1,2]. To date, Eph/ephrin signaling have been considered
to participate in a wide spectrum of developmental
processes, being capable of regulating cellular adhesion,
migration or chemo-repulsion and tissue/cell boundary
formation [4,6].
Beyond their initial role in developmental processes,
Ephs and ephrins have also been involved in a broad range
of processes directly related with tumor progression and
metastasis, including cell attachment and shape, migration
and angiogenesis [7-11]. Notably, Ephs have been consid-
ered as master regulators capable of either stimulating the
activities of oncogenic signaling networks or repressing
them, depending on ephrin stimulation and other con-
textual factors [9]. Several Ephs and/or ephrins are also
expressed in both cancer cells and the tumor micro-
environment, where they influence tumor properties
by enabling aberrant cell-cell communication within and
between tumor compartments. Thus, Eph/ephrin system
has been considered as attractive targets for drug design,
as targeting these molecules could simultaneously inhibit
several aspects of tumor growth and progression [7-11].
Lung cancer is the leading cause of cancer mortality
in the world, causing more deaths than colorectal, breast
and prostate cancers combined [12]. Non small cell lung
cancer (NSCLC) is considered aggressive and highly inva-
sive and accounts for approximately 80% of all lung cancer
cases [13]. Despite the development of new surgical proce-
dures and chemotherapeutic protocols, the 5-year survival
rate remains less than 15% [12,13]. Smoking is the most
important risk factor in the development of most pul-
monary carcinomas [12,13]. However, even in a smoke-
less society, it is predicted that lung cancer due to prior
exposure to carcinogens will continue to be a major health
problem for the future [14,15].
Accumulative clinical evidence has demonstrated that
Ephs are overexpressed in a variety of tumors, being
associated with clinicopathological parameters crucial
for patients’ management and prognosis [7-11,16-19].
However, despite the gradually increasing research in
several human malignancies, there is no comprehensive
available data so far concerning the clinical significance
of Ephs expression in NSCLC. In view of above consid-
erations, the present study aimed to assess immunohis-
tochemically EphA1, A4, A5 and A7 expression in 88
NSCLC patients, in association with clinicopathological
parameters and patients’ survival.
Methods
Clinical Material
Eighty-eight NSCLC specimens obtained from equal num-
ber of patients who underwent surgical resection due to
lung cancer were included in this study. Institutional review
board approval was obtained to use archived materialfor research purposes. None of the patients had re-
ceived chemotherapy or radiation before surgery. Eastern
Cooperative Oncology Group (ECOG) performance status
scoring system was used to assess patients’ daily activ-
ity and capacity. The resected tumors were classified
histologically as lung adenocarcinoma in 56 (63.64%)
and squamous cell lung carcinoma in 32 (36.36%) cases.
The histopathological grading was assessed according
to the criteria described in World Health Organization
(WHO) [20]. Disease histopathological stage was assessed
according to the TNM-system and the criteria of the
International Union against Cancer [21,22]. Histological
parameters, including presence of necrosis, fibrosis, in-
flammation and lymphovascular invasion, were evaluated.
Clinicopathological characteristics of the cohort study are
described in Additional file 1: Table S1 of the supporting in-
formation material. Overall patients’ survival times were de-
fined for the present study. Patients were followed-up for
a time interval between 3 and 121 months (mean: 25.39,
SD: 22.12 months). At the time of the last follow-up, 82
(93.18%) patients had died due to lung cancer, whereas
the remaining 6 (6.82%) patients were alive.
Tissue microarrays (TMAs)
All the archival tissue samples were routinely fixed in
formalin and embedded in paraffin wax. Representative
tissue areas were marked on standard hematoxylin and
eosin stained sections that were cut from the blocks;
these corresponding areas were then punched out of the
paraffin block using a 2.0-mm punch, and the cores were
inserted into a recipient paraffin block.
Immunohistochemistry
Immunostainings were performed on TMAs using
commercially available rabbit polyclonal EphA1 (G-18,
sc-925), EphA4 (S-20, sc-921), EphA5 (C-16, sc-927) and
EphA7 (C-19, sc-918) IgG antibodies (Santa Cruz
Biochemicals, Santa Cruz, CA, USA). Briefly, 4 μm thick
tissue sections were dewaxed in xylene and were
brought to water through graded alcohols. Antigen
retrieval (citrate buffer at pH 6.1 and microwave heating)
was then performed. To remove the endogenous
peroxidase activity, sections were treated with freshly
prepared 0.3% hydrogen peroxide in methanol in the
dark, for 30 minutes (min), at room temperature. Non-
specific antibody binding was blocked using a specific
blocking reagent for rabbit primary antibodies (Sniper,
Biocare Medical, Walnut, Creek, CA, USA) for 5 min.
The sections were then incubated for 1 hour (h), at
room temperature, with primary antibodies, diluted
1:100 in phosphate buffered saline (PBS). After washing
three times with PBS, the sections were incubated at
room temperature with biotinylated linking reagent (Bio-
care Medical) for 10 min, followed by incubation with
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Medical) for 10 min. The resultant immune peroxidase
activity was developed in 0.5% 3,3’-diaminobenzidine
hydrochloride (DAB; Sigma, Saint Louis, MO, USA) in
PBS containing 0.03% hydrogen peroxide for 5 min.
Sections were then counterstained with Harris’s
hematoxylin and mounted in Entellan (Merck, Darmstadt,
Germany). Appropriate negative controls were performed
by omitting the primary antibody and/or substituting it
with an irrelevant anti-serum (data not shown). As
positive control, pancreatic and thyroid cancer tissue sec-
tions with known increased Ephs expression were used
(data not shown) [18,19].Figure 1 Representative immunostainings for EphA1, A4, A5 EphA7
and D, respectively) and of squamous (E, F, G and H, respectively) t
hematoxylin counterstain (original magnification X400).Evaluation of immunohistochemistry
Immunostained slides were evaluated by estimating the
percentage and the intensity of positive cells per TMA
punch by two independent observers (S.T. and P.A.)
blinded to the clinical data, with very good inter-observer
agreement (κ = 0.982, SE: 0.017). At least 2 cores were
analyzed per tumor to assess the EphA1, A4, A5 and A7
immunoreactivity. The immunoreactivity of the tumor
cells for EphA1, A4, A5 and A7 was scored according to
the percentage of EphA1, A4, A5 and A7 positive tumor
cells as 0: negative staining- 0-4% of tumor cells positive;
1: 5-24% of tumor cells positive; 2: 25-49% of tumor cells
positive; 3: 50-100% of tumor cells positive, and itsprotein expression in tumor cells of adenocarcinoma (A, B, C
ype NSCLC. Streptavidin-biotin-peroxidase, DAB chromogen, Harris
Table 1 Associations of Eph-A1 and -A4 expression with clinicopathological characteristics in 88 NSCLC patients
Clinicopathological characteristics Eph-A1 expression Eph-A4 expression
Negative/weak Moderate/high p-value Negative/weak Moderate/high p-value
N = 88 73 (83.0) 15 (17.0) 64 (72.7) 24 (27.3)
Age (mean ± SD;ys) 0.511 0.486
≤ 64.47 ± 9.18 yrs 36 (40.9) 6 (6.8) 32 (36.4) 10 (11.4)
> 64.47 ± 9.18 yrs 37 (42.0) 9 (10.2) 32 (36.4) 14 (15.9)
Gender 0.841 0.693
Female 13 (14.8) 3 (3.4) 11 (12.5) 5 (5.7)
Male 60 (68.2) 12 (13.6) 53 (60.2) 19 (21.6)
Histopathological type 0.748 0.258
Adenocarcimoma 47 (53.4) 9 (10.2) 43 (48.9) 7 (14.8)
Squamous 26 (29.5) 6 (6.8) 21 (23.9) 11 (12.5)
Histopathological grade 0.569 0.963
I + II 48 (54.5) 11 (12.5) 43 (48.9) 16 (18.2)
III 25 (28.4) 4 (4.5) 21 (23.9) 8 (9.1)
Smoking status 0.792 0.837
Yes 65 (73.9) 13 (14.8) 57 (64.8) 21 (23.9)
No 8 (9.1) 2 (2.3) 7 (14.8) 3 (3.4)
Alcohol consumption 0.398 0.503
Systematic 40 (45.5) 10 (11.4) 36 (40.9) 14 (15.9)
No systematic 33 (37.5) 5 (5.7) 28 (31.8) 10 (11.4)
Performance status 0.453 0.469
0-1 63 (71.6) 14 (15.9) 55 (62.5) 22 (25.0)
2 10 (11.4) 1 (1.1) 9 (10.2) 2 (2.3)
Inflammation 0.869 0.026
Yes 16 (18.2) 3 (3.4) 10 (11.4) 9 (10.2)
No 57 (64.8) 12 (13.6) 54 (61.4) 15 (17.0)
Lymphovascular invasion 0.788 0.273
Yes 22 (25.0) 4 (4.5) 21 (23.9) 5 (5.7)
No 51 (58.0) 11 (12.5) 43 (48.9) 19 (21.6)
Necrosis 0.785 0.253
Yes 41 (46.6) 9 (10.2) 34 (38.6) 16 (18.2)
No 32 (36.4) 6 (6.8) 30 (34.1) 8 (9.1)
Fibrosis 0.593 0.821
Yes 14 (15.9) 2 (2.3) 12 (13.6) 4 (4.5)
No 59 (67.0) 13 (14.8) 52 (59.1) 20 (22.7)
Tumor size 0.941 0.700
T1 14 (15.9) 3 (3.4) 13 (14.8) 4 (4.5)
T2-4 59 (67.0) 12 (13.6) 51 (58.0) 20 (22.7)
Lymph node metastases 0.091 0.062
N0-1 47 (53.4) 13 (14.8) 40 (45.5) 20 (22.7)
N1-2 26 (29.5) 2 (2.3) 24 (27.3) 4 (4.5)
Distant metastases 0.250 0.120
M0 67 (76.1) 15 (17.0) 58 (65.9) 24 (27.3)
M1 6 (6.8) 0 (0.0) 6 (6.8) 0 (0.0)
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Table 1 Associations of Eph-A1 and -A4 expression with clinicopathological characteristics in 88 NSCLC patients
(Continued)
Histopathological stage 0.185 0.047
I + II 40 (45.5) 11 (12.5) 33 (37.5) 18 (20.5)
III + IV 33 (37.5) 4 (4.5) 31 (35.2) 6 (6.8)
Ki-67 protein statement 0.047 0.104
< mean value 35 (39.8) 3 (3.4) 31 (35.2) 7 (8.0)
≥ mean value 38 (43.2) 12 (13.6) 33 (37.5) 17 (19.3)
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mediate staining; 3: intense staining. Finally, the ex-
pression of EphA1, A4, A5 and A7 was classified as
negative/weak; if the total score was 0 or 2 and moderate/
high; if the total score was ≥3. In this way, we ensure that
each group has a sufficient and more homogeneous num-
ber of cases in order to be comparable with the other
groups [18,19,23].
Statistical analysis
Chi-square test was used to assess the associations of
EphA1, A4, A5 and A7 protein expression with clinico-
pathological variables. Survival curves were constructed
using the Kaplan-Meier method and the differences be-
tween the curves were compared by the log-rank test. A
Cox proportional-hazard regression model was developed
to evaluate the association between the potential prognostic
marker and overall patients’ survival. A p-value less than
0.05 was considered the limit of statistical significance.
SPSS for Windows Software was used for all analyses
(SPSS Inc., 2003, Chicago, USA).
Results
Moderate/high EphA1, A4, A5 and A7 expression was
noted in 15 (17.0%), 24 (27.3%), 51 (58.0%) and 50
(56.8%) out of 88 NSCLC cases, respectively. Of the 56
adenocarcinoma-type NSCLC cases, moderate/high EphA1,
A4, A5 and A7 expression was noted in 9 (16.1%), 13
(23.2%), 35 (62.5%) and 33 (58.9%), respectively. Of the
32 squamous-type NSCLC cases, moderate/high EphA1,
A4, A5 and A7 expression was noted in 6 (18.8%), 11
(34.4%), 16 (50.0%) and 17 (53.1%) cases, respectively.
EphA1, A4 and A5 presented mainly cytoplasmic and
occasionally membraneous pattern of staining, whereas
EphA7 showed both cytoplasmic and nuclear pattern
of staining (Figure 1).
EphA1 expression did not show significant associations
with any clinicopathological parameters examined except
for a trend of correlation with lymph node metastases
(Table 1). A slightly increased incidence of moderate/high
EphA1 expression was observed in NSCLC cases of low
histopathological stage, as well as in those presenting
absence of distant metastasis (Table 1). Moderate/highEphA4 expression was significantly associated with low
stage and presence of inflammation and borderline with
lymph node metastases (Table 1). Eph-A5 expression
did not show significant associations except for a trend
of correlation with patients’ age (Table 2). Moderate/high
EphA7 expression was significantly more frequently ob-
served in older patients, as well as in those with presence
of fibrosis and smaller tumor size (Table 2). EphA1, A5
and A7 expression was significantly positively associated
with tumor proliferative capacity (Tables 1 and 2). Squa-
mous cell lung carcinoma patients showed a no significant
increased incidence of moderate/high EphA4 compared to
those with adenocarcinoma (Table 1), while moderate/
high EphA5 and A7 expression was more frequently
observed in lung adenocarcinoma patients compared
to those with squamous cell carcinoma (Table 2). A no
significant increased incidence of moderate/high EphA5
and A7 expression was also observed in NSCLC patients
presenting low stage and well/moderately differentiation
(Table 2). Moderate/high EphA1, A4, A5 and A7 expres-
sion was more frequently observed in NSCLC patients
with ECOG performance status < 2 compared to those
with ECOG performance status ≥ 2, at a non significant
level (Tables 1 and 2).
In univariate survival analysis, histopathological type and
stage, ECOG performance status and EphA4, A5 and A7
expression were identified as significant prognostic factors
of patients’ survival (Table 3, Cox regression analysis, p =
0.013, p < 0.001, p = 0.018, p = 0.025, p = 0.012 and p =
0.016, respectively). Kaplan-Meier survival curves indicated
that NSCLC patients presenting moderate/high EphA4, A5
or A7 expression showed significantly longer survival times
compared to those with negative/weak expression (Figure 2,
log-rank test, p = 0.019, p = 0.006 and p = 0.012, respect-
ively). In multivariate analysis, adjusting for histopatho-
logical type and stage and ECOG performance status,
EphA4 and A7 expression were identified as independent
prognostic factors of patients’ survival (Tables 4 and 5, Cox
regression analysis, p = 0.029 and p = 0.044, respectively),
whereas EphA5 expression did not remain significant
(Table 6, Cox regression analysis, p = 0.068).
Statistical analysis was further performed within each
NSCLC histopathological type. EphA1 expression was
Table 2 Associations of Eph-A5 and -A7 expression with clinicopathological characteristics in 88 NSCLC patients
Clinicopathological characteristics Eph-A5 expression Eph-A7 expression
Negative/weak Moderate/high p-value Negative/weak Moderate/high p-value
N = 88 37 (42.0) 51 (58.0) 38 (43.2) 50 (56.8)
Age (mean ± SD;ys) 0.061 0.036
≤ 64.47 ± 9.18 yrs 22 (25.0) 20 (22.7) 23 (26.1) 19 (21.6)
> 64.47 ± 9.18 yrs 15 (17.0) 31 (35.2) 15 (17.0) 31 (35.2)
Gender 0.333 0.287
Female 5 (5.7) 11 (12.5) 5 (5.7) 11 (12.5)
Male 32 (36.4) 40 (45.5) 33 (37.5) 39 (44.3)
Histopathological type 0.235 0.597
Adenocarcimoma 21 (23.9) 35 (39.8) 23 (26.1) 33 (37.5)
Squamous 16 (18.2) 16 (18.2) 15 (17.0) 17 (19.3)
Histopathological grade 0.406 0.499
I + II 23 (26.1) 36 (40.9) 24 (27.3) 35 (39.8)
III 14 (15.9) 15 (17.0) 14 (15.9) 15 (17)
Smoking status 0.412 0.829
Yes 34 (38.6) 44 (50.0) 34 (38.6) 44 (50.0)
No 3 (3.4) 7 (8.0) 4 (4.5) 6 (6.8)
Alcohol consumption 0.389 0.489
Systematic 23 (26.1) 27 (30.7) 20 (22.7) 30 (34.1)
No systematic 14 (15.9) 24 (27.3) 18 (20.5) 20 (22.7)
Performance status 0.369 0.626
0-1 31 (35.2) 46 (52.3) 34 (38.6) 43 (48.9)
2 6 (6.8) 5 (5.7) 4 (4.5) 7 (8.0)
Inflammation 0.297 0.529
Yes 6 (6.8) 13 (14.8) 7 (8.0) 12 (13.6)
No 31 (35.2) 38 (43.2) 31 (35.2) 38 (43.2)
Lymphovascular invasion 0.328 0.403
Yes 13 (14.8) 13 (14.8) 13 (14.8) 13 (14.8)
No 24 (27.3) 38 (43.2) 25 (28.4) 37 (42.0)
Necrosis 0.656 0.540
Yes 20 (22.7) 30 (34.1) 23 (26.1) 27 (30.7)
No 17 (19.3) 21 (23.9) 15 (17.0) 23 (26.1)
Fibrosis 0.879 0.029
Yes 7 (8.0) 9 (10.2) 3 (3.4) 13 (14.8)
No 30 (34.1) 42 (47.7) 35 (39.8) 37 (42.0)
Tumor size 0.530 0.018
T1 6 (6.8) 11 (12.5) 3 (3.4) 14 (15.9)
T2-4 31 (35.2) 40 (45.5) 35 (39.8) 36 (40.9)
Lymph node metastases 0.302 0.179
N0-1 23 (26.1) 37 (42.0) 23 (26.1) 37 (42.0)
N1-2 14 (15.9) 14 (15.9) 15 (17.0) 13 (14.8)
Distant metastases 0.206 0.229
M0 33 (37.5) 49 (55.7) 34 (38.6) 48 (54.5)
M1 4 (4.5) 2 (2.3) 4 (4.5) 2 (2.3)
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Table 2 Associations of Eph-A5 and -A7 expression with clinicopathological characteristics in 88 NSCLC patients
(Continued)
Histopathological stage 0.285 0.378
I + II 19 (21.6) 32 (36.4) 20 (22.7) 31 (35.2)
III + IV 18 (20.5) 19 (21.6) 18 (20.5) 19 (21.6)
Ki-67 protein statement 0.002 0.046
< mean value 23 (26.1) 15 (17.0) 21 (23.9) 17 (19.3)
≥ mean value 14 (15.9) 36 (40.9) 17 (19.3) 33 (37.5)
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(data not shown) or patients’ survival in both subgroups
(Figures 3 and 4) except for a borderline association
with tumor proliferative capacity in the subgroup of lung
adenocarcinoma (p = 0.053).
In the subgroup of lung adenocarcinoma, EphA4 and
A5 expression showed trends of correlation with overall
patients’ survival (Figure 3, log-rank test, p = 0.093 and
p = 0.072, respectively), while EphA7 expression was
significantly associated with overall patients’ survival in
both univariate (Figure 3, log-rank test, p = 0.017) and
multivariate analysis (Cox regression analysis, p = 0.005).
EphA4 expression was significantly associated with theTable 3 Association of clinicopathological parameters and Ep
Univariate analysis
Clinicopathological variables
Age (≤64.47 ± 9.18 / > 64.47 ± 9.18 yrs)
Gender (Male/Female)
Histopathological type (Adenocarcinoma/Squamous)









Lymph node metastases (N0-1/N2-3)
Distant metastases (M0/M1)
Histopathological stage (I + II/III + IV)
EphA1 expression (Negative/Weak vs Moderate/Strong)
EphA4 expression (Negative/Weak vs Moderate/Strong)
EphA5 expression (Negative/Weak vs Moderate/Strong)
EphA7 expression (Negative/Weak vs Moderate/Strong)presence of inflammation (p = 0.025) and EphA5 expression
with tumor proliferative capacity (p = 0.023). EphA7
expression was significantly associated with patients’ age
(p = 0.026) and borderline with tumor size (p = 0.085).
Moderate/high EphA1, A4, A5 and A7 expression was
more frequently observed in lung adenocarcinoma patients
with ECOG performance status < 2 compared to those
with ECOG performance status ≥ 2, at a non significant
level (p > 0.05, data not shown).
In the subgroup of squamous cell lung carcinoma,
EphA1, A5 and A7 expression did not affect patients’
survival (Figure 4, log-rank test, p = 0.294, p = 0.125
and p = 0.621, respectively), while no association withhA1, A4, A5 and A7 expression with patients’ survival:
Overall patients’ survival


































































































Low Eph-A7 expression p=0.012
D
Figure 2 Kaplan-Meier survival analysis stratified according to A. EphA1, B. EphA4, C. EphA5 and D. EphA7 expression in 88 NSCLC
patients (–complete cases; + censored cases).
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EphA4 expression was significantly associated with overall
patients’ survival in univariate (Figure 4, log-rank test,
p = 0.045) but not in multivariate analysis after adjustment
for histopathological stage (Cox-regression analysis,
p = 0.186). EphA5 and A7 expression was significantly
positively associated with tumor proliferative capacity
(p = 0.006 and p = 0.028, respectively), while EphA4 ex-
pression showed a trend of correlation (p = 0.083). EphA7
expression showed trends of correlation with the presence
of fibrosis (p = 0.070) and tumor size (p = 0.081).
Discussion
In the last few years, accumulative evidence has suggested
that Ephs and ephrins are frequently overexpressed in aTable 4 Cox regression model including histopathological
type and stage, performance status and EphA4 expression




Histopathological stage (I + II/III + IV) 2.627 (1.629-4.238) <0.001
Performance status (0–1/2) 2.355 (1.212-4.573) 0.011
EphA4 expression
(Negative/Weak vs Moderate/Strong)
0.544 (0.315-0.939) 0.029variety of human malignancies, including oesophageal,
thyroid, breast, gastric, colon, pancreatic and gynaecological
carcinomas, melanomas and neuroblastomas [7-11,16-19].
However, the most comprehensive clinical data so far
is restricted to EphA2 receptor and not extending to
other members of the Eph family, while the assessment
of the clinical significance of Ephs in lung cancer remains
still scarce.
In this aspect, the present study supported clinical
evidence for possible participation of Ephs in the bio-
logical mechanisms underlying the carcinogenic evolu-
tion of NSCLC. Although several previous studies have
documented the clinical significance of EphA1 in a variety
of malignant tumors including, pancreatic, breast, colorec-
tal, urothelial, vulvar and non-melanoma skin carcinomaTable 5 Cox regression model including histopathological
type and stage, performance status and EphA7 expression




Histopathological stage (I + II/III + IV) 2.779 (1.729-4.466) <0.001




Table 6 Cox regression model including histopathological
type and stage, performance status and EphA5 expression




Histopathological stage (I + II/III + IV) 2.207 (1.684-4.352) <0.001
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with clinicopathological parameters and patients’ survival.
However, its possible involvement in the biological
mechanisms underlying NSCLC should not be excluded,
since the increased incidence of moderate/high EphA1
expression observed in low stage NSCLC patients, as
well as in those presenting absence of distant metastasis
may reach statistical significance in larger cohorts. Notably,
we found that elevated EphA4, A5 and A7 expression was
significantly associated with favourable prognosis. Elevated
EphA4 expression was also significantly associated with low
stage and presence of inflammation, while enhanced EphA7
expression with older patients’ age, presence of fibrosis and
smaller tumor size. Elevated EphA1, A4, A5 and A7 expres-






































Low Eph-A5 expression p=0.072
C
Figure 3 Kaplan-Meier survival analysis stratified according to A. Eph
adenocarcinoma-type NSCLC patients (–complete cases; + censored ccapacity. Moreover, the present study showed an elevated
EphA1, A4, -A5 and A7 expression in NSCLC patients
with ECOG performance status < 2, which reinforces the
assumption that such an association may reach statistical
significance in larger cohorts. Overall, these findings sup-
ported evidence that Eph signaling may be more import-
ant in non advanced stages of lung cancer disease.
In line with the present findings, sufficient evidence has
recently suggested that Ephs are implicated in lung tumor
cell biology [28]. In fact, immunohistochemical analysis on
279 NSCLC cases indicated that elevated EphA2 expression
was associated with K-Ras mutations, EGFR activation,
smoking history and poor prognosis [29]. Enhanced EphA2
levels were also reported in patients who subsequently
developed brain metastases, whereas reduced EphA2
levels identified patients who did not relapse or who devel-
oped contralateral lung metastasis [30]. Moreover, elevated
EphA2/ephrin-A1 expression was associated with female
gender, reduced smoking status, adenocarcinoma type,
well differentiated and p-stage IA NSCLC and EGFR gene
mutations [31]. This study also showed that elevated
EphA2 mRNA expression in p-stage I NSCLC patients
was positively related to improved prognosis [31]. An-
other study analyzing 11 Ephs and 8 ephrins, indicated
that EphA4 and ephrin-A1 gene expression was associated
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Figure 4 Kaplan-Meier survival analysis stratified according to A. EphA1, B. EphA4, C. EphA5 and D. EphA7 expression in 32
squamous-type NSCLC patients (–complete cases; + censored cases).
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[32]. Moreover, decreased EphB6 expression mRNA and
protein levels were reported to be associated with increased
risk for metastasis development in NSCLC patients
[33]. Several mutations in Eph family members, including
EphA3, A5, A7, B1 and B6 were identified in lung adeno-
carcinoma, while advanced stage tumours presented accu-
mulated more EphA7 mutations compared to low stage
tumours [34]. More recently, EphB4 expression was corre-
lated with differentiation, lymph node metastasis and TNM
stage in 28 NSCLC patients, while the polymorphism in
EphB4 at rs314310 appeared to correspond to protein
expression and disease susceptibility [35].
Pre-clinical studies have provided compelling evidence
that members of the Eph family and their ligands may
promote tumor growth, invasion and metastasis and
neovascularization [9,17,36]. Tumor suppressive roles
have also been reported for Eph receptors, and ligand-
dependent vs ligand-independent signaling has been
considered as one key mechanism underlying tumor sup-
pressive function as opposed to oncogenic effects [9,17,36].
Thus, Eph receptors and their ligands can switch between
contrasting activities by using bidirectional signalling,
as well as other signalling modalities to influence cancer
cell behaviour [9,36]. Taking into consideration the above
notions, our findings supported evidence that Ephreceptors may be considered as potential regulators capable
of repressing the activities of oncogenic signalling in
NSCLC progression, depending on ephs stimulation and/or
other contextual factors.
Interestingly, accumulative in vitro and in vivo evidence
has suggested that Ephs and their ligands, may represent
promising therapeutic targets in cancer [9,17,28,37]. A
variety of strategies are currently under evaluation to
interfere with their tumor-promoting effects or enhance
their tumor-suppressing effects [9,17,28]. Recently, EphA2/
ephrin-A1 system has been considered as potential drug
target using multiple approaches, such as agonist antibodies,
RNA interference, immunotherapy, virus vector-mediated
gene transfer, small-molecule inhibitors and nanoparticles
[36]. In addition, the functional cross-talk of EphA2 with
other oncogenic alterations along in conjunction with en-
couraging results from pre-clinical combined studies with
chemotherapeutic drugs or molecular therapies has rein-
forced the utility of combination therapies in targeting
Ephs overexpression in cancer [36]. Notably, EphA2 siRNA
when used in combination with chemotherapeutic drug
paclitaxel was more effective in inhibiting growth of HeyA8
or SKOV3 orthotopic ovarian tumors in mice compared to
treatment with the control siRNA and paclitaxel [38].
A combination of EphA2 and focal adhesion kinase
(FAK) siRNA resulted in significant decrease in ovarian
Giaginis et al. BMC Clinical Pathology 2014, 14:8 Page 11 of 12
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to monotherapy [39]. EphA2 overexpression was also iden-
tified as a contributing factor towards the development of
resistance to Her2-targeted trastutzumab monoclonal anti-
body therapy [40]. The cross-talk between EphA2 and
EGFR signalling supported evidence that simultaneously
inhibiting both EphA2 and EGFR overexpression may
provide better anti-tumor response [41].Conclusions
The present study supported clinical evidence for pos-
sible participation of EphA1, A4, A5 and A7 in the bio-
logical mechanisms underlying the carcinogenic
evolution of NSCLC. Of even more clinical significance
are the data supporting the potential role of EphA4, A5
and A7 members in the pathophysiological aspects of the
disease that affect patients’ survival. These findings sug-
gested an important potential role of Ephs pathway signal-
ling in non advanced stage NSCLC. Further research
conducted on large cohorts that additionally concern
more sensitive techniques is strongly recommended. Fu-
ture studies investigating the soluble/secreted form of
Ephs are also recommended in view of the fact that sol-
uble/secreted forms of these proteins may have a poten-
tial to distinguish tumour histopathological type in lung
cancer [42]. Understanding the complexity of Ephs par-
ticipation in NSCLC could contribute to the elucidation
of the mechanisms underlining lung cancer progression
and metastasis that may in turn support the develop-
ment of novel anti-cancer therapies targeting Eph/
ephrin signalling system in this type of human
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